Adam Jendrisak

1.6k total citations · 1 hit paper
32 papers, 988 citations indexed

About

Adam Jendrisak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Adam Jendrisak has authored 32 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Adam Jendrisak's work include Prostate Cancer Treatment and Research (18 papers), Cancer Genomics and Diagnostics (17 papers) and Cancer Cells and Metastasis (16 papers). Adam Jendrisak is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Cancer Genomics and Diagnostics (17 papers) and Cancer Cells and Metastasis (16 papers). Adam Jendrisak collaborates with scholars based in United States, United Kingdom and Ireland. Adam Jendrisak's co-authors include Ryan Dittamore, Ryon P. Graf, Jessica Louw, Howard I. Scher, Nicole A. Schreiber, Dena Marrinucci, David Lu, Martin Fleisher, Brigit McLaughlin and Stephanie Greene and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Adam Jendrisak

29 papers receiving 974 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

2016 461 citations Howard I. Scher, David Lu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Jendrisak United States	10	679	518	510	255	104	32	988
Jessica Louw United States	9	692 1.0×	532 1.0×	479 0.9×	249 1.0×	114 1.1×	30	988
Penelope Flohr United Kingdom	10	771 1.1×	555 1.1×	302 0.6×	439 1.7×	89 0.9×	25	1.1k
Mateus Crespo United Kingdom	17	525 0.8×	393 0.8×	421 0.8×	399 1.6×	97 0.9×	44	1.0k
Wendy Onstenk Netherlands	19	397 0.6×	456 0.9×	455 0.9×	257 1.0×	86 0.8×	25	813
John L. Silberstein United States	12	728 1.1×	323 0.6×	413 0.8×	314 1.2×	126 1.2×	16	1.0k
Aseem Anand United States	17	668 1.0×	313 0.6×	383 0.8×	135 0.5×	345 3.3×	33	865
Bram De Laere Belgium	14	519 0.8×	438 0.8×	339 0.7×	232 0.9×	115 1.1×	35	793
Sara Ravaioli Italy	16	439 0.6×	330 0.6×	351 0.7×	258 1.0×	212 2.0×	54	939
Kevin Beja Canada	16	1.4k 2.0×	1.0k 2.0×	545 1.1×	552 2.2×	157 1.5×	25	1.7k
Bryce Lakely United States	13	378 0.6×	208 0.4×	239 0.5×	295 1.2×	68 0.7×	16	619

Countries citing papers authored by Adam Jendrisak

Since Specialization

Citations

This map shows the geographic impact of Adam Jendrisak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Jendrisak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Jendrisak more than expected).

Fields of papers citing papers by Adam Jendrisak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Jendrisak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Jendrisak. The network helps show where Adam Jendrisak may publish in the future.

Co-authorship network of co-authors of Adam Jendrisak

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Jendrisak. A scholar is included among the top collaborators of Adam Jendrisak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Jendrisak. Adam Jendrisak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conteduca, Vincenza, Sheng‐Yu Ku, Jerry Lee, et al.. (2021). Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. npj Precision Oncology. 5(1). 76–76. 22 indexed citations

Zhang, Bingnan, C. Allison Stewart, Carl M. Gay, et al.. (2021). Abstract 384: Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer. Cancer Research. 81(13_Supplement). 384–384. 6 indexed citations

Shenderov, Eugene, Karim Boudadi, Wei Fu, et al.. (2021). Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial. The Prostate. 81(6). 326–338. 47 indexed citations

Jendrisak, Adam, Jerry Lee, Ángel Rodríguez, et al.. (2020). Abstract P4-01-03: Computer vision and machine learning allows for the prediction of genomic instability using circulating tumor cell morphology in triple negative breast cancer patients. Cancer Research. 80(4_Supplement). P4–1. 2 indexed citations

Lu, David, Rachel Krupa, Melissa Harvey, et al.. (2020). Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer. SHILAP Revista de lepidopterología. 9(1). 13–19. 8 indexed citations

Schonhoft, Joseph D., Jimmy L. Zhao, Adam Jendrisak, et al.. (2020). Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research. 80(22). 4892–4903. 32 indexed citations

Scher, Howard I., Adam Jendrisak, Audrey Gill, et al.. (2020). Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane.. Journal of Clinical Oncology. 38(15_suppl). 5572–5572.

Jendrisak, Adam, et al.. (2019). Functional cell profiling (FCP) of ∼100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC subtypes within and between cancer types. Annals of Oncology. 30. v797–v798.

Vansant, Gordon, Adam Jendrisak, Joseph D. Schonhoft, et al.. (2018). Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.. Journal of Clinical Oncology. 36(15_suppl). 1084–1084. 2 indexed citations

10.

Dittamore, Ryan, Yipeng Wang, Stephanie Daignault‐Newton, et al.. (2018). Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.. Journal of Clinical Oncology. 36(15_suppl). 5012–5012. 2 indexed citations

11.

Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2017). Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research. 77(20). 5687–5698. 94 indexed citations

12.

Krupa, Rachel, David Lu, Ryon P. Graf, et al.. (2016). Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer. Journal of Thoracic Oncology. 11(2). S52–S52. 1 indexed citations

13.

Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.. Journal of Clinical Oncology. 34(2_suppl). 446–446. 3 indexed citations

14.

Graf, Ryon P., David Lu, Rachel Krupa, et al.. (2016). PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals of Oncology. 27. vi22–vi22. 1 indexed citations

15.

Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 16(1). 744–744. 90 indexed citations

16.

Scher, Howard I., Ryon P. Graf, Jessica Louw, et al.. (2016). Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.. Journal of Clinical Oncology. 34(2_suppl). 163–163. 2 indexed citations

17.

Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.. Journal of Clinical Oncology. 34(15_suppl). 4527–4527. 9 indexed citations

18.

Beltran, Himisha, Adam Jendrisak, Mark Landers, et al.. (2015). The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research. 22(6). 1510–1519. 108 indexed citations

19.

Scher, Howard I., Jessica Louw, Adam Jendrisak, et al.. (2015). Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 147–147. 3 indexed citations

20.

Bambury, Richard, Jessica Louw, Rachel Krupa, et al.. (2014). Characteristics of De Novo Resistance to Androgen Targeting Therapeutics (Ar Tx) Through Circulating Tumor Cells (Ctcs) Analysis in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients. Annals of Oncology. 25. iv79–iv79. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact